Paul Moore
Chief Scientific Officer Zymeworks
Seminars
Wednesday 9th September 2026
Tumor Selectivity Strategies Across Multispecifics, TCEs, & ADCs: What Have we Learnt so Far?
11:40 am
- Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
- Discussing dual-target and multispecific approaches
- Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC
Thursday 10th September 2026
Reflecting on the First Attempts with Novel Payloads, & What we are Doing Differently Now
8:45 am
- What is the path to success for novel payloads, including how to navigate early assessment of payload platforms?
- What are the challenges when doing something different and how are we decreasing risk when translating preclinical optimism into clinical success?
- Discussing the panellists’ approach to business development. What would a win/ win business deal look like that focuses on payloads?
